In The Know-September 2023

September 2023
Pdf Summary
Ed’s List for September 2023 presents a curated selection of significant literature in gynecologic oncology, prepared by Ed Pavlik from the University of Kentucky Medical Center. The document includes comprehensive reviews and studies that highlight advancements, findings, and discussions in this field. <br /><br />Key topics and studies featured include:<br /><br />1. **Validation of the 2023 FIGO Staging Schema for Advanced Endometrial Cancer**: This study by Matsuo et al. in the European Journal of Cancer evaluates the prognostic ability of the revised 2023 FIGO staging for advanced endometrial cancer. The revision includes detailed sub-groupings based on anatomical site and histologic subtype.<br /><br />2. **Adoptive Transfer of Vaccine-Primed Autologous T Cells in Ovarian Cancer**: Bobisse et al. in Nat Cancer report a phase 1 trial showing that the adoptive transfer of vaccine-primed T cells can reinvigorate immune responses in ovarian cancer, demonstrating safety and potential clinical benefits.<br /><br />3. **HPV and Host DNA Methylation Score for Cervical Adenocarcinoma Detection**: Gradissimo et al. in JNCI propose a novel methylation score for HPV16/18/45 and host genes to better screen for AIS and ADC, improving sensitivity and specificity in detection.<br /><br />4. **Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer**: Two studies — one from the Lancet Oncology and another from JAMA Surgery — confirm the long-term survival benefits and improved outcomes of adding HIPEC to cytoreductive surgery in advanced-stage ovarian cancer.<br /><br />5. **SOD1 Targeting via RNAi for Platinum-Resistant Ovarian Cancer**: A study in Cancer Gene Therapy by Szenasi et al. highlights the potential of targeting SOD1 with PEGylated graphene oxide nanoparticles to overcome platinum resistance in ovarian cancer.<br /><br />6. **MMR/MSI Discordance in Endometrial Cancers**: Riedinger et al. in Cancer investigate the discordance between MMR and MSI testing, revealing heterogeneity in MMR expression and its implications for Lynch syndrome diagnosis and recurrence rates.<br /><br />7. **Mechanisms of PARP Inhibitor Resistance via cfDNA**: Lheureux et al. in Clinical Cancer Research explore cfDNA to detect resistance mechanisms to PARP inhibitors in ovarian cancer, offering insights into mutation identification and therapeutic strategy adjustments.<br /><br />8. **Geographic Variation in Cervical Cancer Rates**: Leath et al. in AJCO analyze Medicaid claims data to identify trends in cervical and metastatic cervical cancer incidence, highlighting areas with high or increasing cancer burden.<br /><br />9. **Clinical Trial Participation and Survival in Platinum-Resistant Ovarian Cancer**: Morton et al. highlight that participation in clinical trials is associated with improved overall survival compared to standard care for patients with platinum-resistant ovarian cancer.<br /><br />10. **Surgeon and Patient Outcomes**: Wallis et al. in JAMA Surg report that patients treated by female surgeons have lower rates of adverse outcomes postoperatively compared to those treated by male surgeons.<br /><br />The aforementioned articles and other studies included in Ed’s List serve to update practitioners and researchers in gynecologic oncology on recent findings, advances in treatment, methodology validations, and clinical outcomes, promoting informed decisions and advancements in patient care.
Keywords
gynecologic oncology
endometrial cancer staging
ovarian cancer T cells
cervical adenocarcinoma detection
HIPEC surgery
platinum-resistant ovarian cancer
MMR/MSI discordance
PARP inhibitor resistance
cervical cancer rates
clinical trial participation